Drilldown: Medicines
Appearance
Medicines > onset
:
1–2 h (PO), immediate (IV)
or
Postprandial glucose effect within days; HbA1c by 12 weeks 
:
1–2 h (PO), immediate (IV)
or
Postprandial glucose effect within days; HbA1c by 12 weeks 
Use the filters below to narrow your results.
None (1) ·
Non-selective competitive antagonist at β1 and β2 adrenergic receptors. Lipophilic; significant blood–brain barrier penetration, accounting for its CNS effects. (1) ·
'"`UNIQ--vote-00000762-QINU`"' Largely renally cleared, hence the eGFR-tiered dosing. Rare but well-documented signals: acute pancreatitis (uncertain causal contribution), severe joint pain, and bullous pemphigoid (class effect, especially in older Asian patients)'"`UNIQ--ref-00000763-QINU`"'. (1)
Showing below up to 3 results in range #1 to #3.

